Agios Pharmaceuticals (NASDAQ:AGIO – Get Free Report) is one of 843 public companies in the “Biotechnology” industry, but how does it weigh in compared to its competitors? We will compare Agios Pharmaceuticals to related companies based on the strength of its valuation, institutional ownership, analyst recommendations, earnings, dividends, risk and profitability.
Analyst Recommendations
This is a summary of recent ratings and target prices for Agios Pharmaceuticals and its competitors, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Agios Pharmaceuticals | 1 | 3 | 5 | 1 | 2.60 |
| Agios Pharmaceuticals Competitors | 9924 | 15317 | 45695 | 1603 | 2.54 |
Agios Pharmaceuticals currently has a consensus price target of $42.12, indicating a potential upside of 39.72%. As a group, “Biotechnology” companies have a potential upside of 131.45%. Given Agios Pharmaceuticals’ competitors higher probable upside, analysts clearly believe Agios Pharmaceuticals has less favorable growth aspects than its competitors.
Valuation & Earnings
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Agios Pharmaceuticals | $54.03 million | -$412.78 million | -4.77 |
| Agios Pharmaceuticals Competitors | $690.32 million | $9.48 million | -18.32 |
Agios Pharmaceuticals’ competitors have higher revenue and earnings than Agios Pharmaceuticals. Agios Pharmaceuticals is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Risk & Volatility
Agios Pharmaceuticals has a beta of 0.66, meaning that its stock price is 34% less volatile than the S&P 500. Comparatively, Agios Pharmaceuticals’ competitors have a beta of -1.84, meaning that their average stock price is 284% less volatile than the S&P 500.
Profitability
This table compares Agios Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Agios Pharmaceuticals | -264.76% | -34.63% | -32.04% |
| Agios Pharmaceuticals Competitors | -12,319.70% | -407.93% | -30.95% |
Institutional & Insider Ownership
47.8% of shares of all “Biotechnology” companies are held by institutional investors. 5.4% of Agios Pharmaceuticals shares are held by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Summary
Agios Pharmaceuticals competitors beat Agios Pharmaceuticals on 7 of the 13 factors compared.
About Agios Pharmaceuticals
Agios Pharmaceuticals is a biopharmaceutical company focused on developing medicines for rare genetic diseases, particularly blood disorders. Based in Cambridge, Massachusetts, the company applies research into cellular metabolism to identify potential treatments. Its marketed medicine, PYRUKYND (mitapivat), is approved in the United States to treat adults with pyruvate kinase deficiency, a rare inherited disorder that can cause anemia. Agios also develops therapies for other rare diseases, including additional blood disorders.
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
